Combined Evaluation of AFP, CA15-3, CA125, CA19-9, and CEA Tumor Markers in Patients with Hepatitis B and C

被引：0

作者：

Assmar, Mehdi ^{[1
]}

Yeganeh, Sara ^{[1
]}

Mansourghanaei, Fariborz ^{[2
]}

Amirmozafari, Nour ^{[3
]}

机构：

[1] Islamic Azad Univ, Dept Microbiol, Lahijan, Iran

[2] Guilan Univ Med Sci, Gastrointestinal & Liver Dis Res Ctr, Rasht, Iran

[3] Iran Univ Med Sci, Sch Med, Dept Microbiol, Tehran, Iran

来源：

IRANIAN JOURNAL OF PUBLIC HEALTH | 2016年 / 45卷 / 12期

关键词：

Tumor markers; Hepatitis B; Hepatitis C; ELISA; CLINICAL-IMPLICATIONS; ALPHA-FETOPROTEIN; LIVER-DISEASE; SERUM; CANCER; EPIDEMIOLOGY; PREVALENCE; INFECTION; ANTIGEN;

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Background: This study aimed to determine the role of tumor markers AFP, CA15-3, CA125, CA19-9 and CEA in patients with hepatitis B and C. Methods: This descriptive cross-sectional study was performed from Oct 2012 to Oct 2014. Serum samples of 129 patients with hepatitis B and C referred to Guilan Liver and Digestive Disease Research Center in Rasht, Iran were collected and checked for the existence of the listed tumor markers by ELISA. Results: No increase in serum levels of tumor marker CA19-9, CEA and CA15-3 were seen in patients with hepatitis (P>0.05). In patients with hepatitis B, increase in CA125 were observed (P=0.03). In hepatitis C patients, there was an increase in AFP levels (P=0.03). Conclusion: The levels of AFP and CA125 markers were high in hepatitis C and hepatitis B, respectively. However, the increased levels were not seen is malignancy. Due to the small sample size, further study is necessary to find the reasons of the increase.

引用

页码：1645 / 1651

页数：7

共 50 条

[41] 健康体检人群血清AFP、CEA、CA125、CA19-9检测结果分析
邹玲莉
胡梅琮
汤浩舟
浙江医学, 2013, 35 (13) : 1298 - 1300
[42] Development of ELISA on 384-well microplate for AFP,CA125,CA19-9 and CA15-3: higher test sensitivity and lower reagent cost.
Chang, PY
Wu, JT
Sun, YC
CLINICAL CHEMISTRY, 2001, 47 (06) : A125 - A126
[43] THE VALUE OF CA19-9 AND CA15-3 ANTIGENS IN THE IMMUNOHISTOCHEMICAL EVALUATION OF CARCINOMAS
GATALICA, Z
MIETTINEN, M
LABORATORY INVESTIGATION, 1994, 70 (01) : A16 - A16
[44] Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy
Zhipeng Sun
Nengwei Zhang
World Journal of Surgical Oncology, 12
[45] CLINICAL EVALUATION OF CEA, CA125, CA19-9 AND CA72-4 IN GASTRIC CANCER PATIENTS WITH ADJUVANT CHEMOTHERAPY
Abbas, M.
Fransis, S.
Naveed, M.
Mohammad, I. S.
Tengli, C.
Nepal, A.
Thao, D. T.
Meiqi, S.
Dingding, C.
VALUE IN HEALTH, 2017, 20 (09) : A732 - A732
[46] Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy
Sun, Zhipeng
Zhang, Nengwei
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2014, 12
[47] Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions
Li, C. -S.
Cheng, B. -C.
Ge, W.
Gao, J. -F.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (03) : 444 - 448
[48] Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor
Tamakoshi, K
Kikkawa, F
Shibata, K
Tomoda, K
Obata, NH
Wakahara, F
Tokuhashi, Y
Ishikawa, H
Kawai, M
Tomoda, Y
GYNECOLOGIC ONCOLOGY, 1996, 62 (01) : 67 - 72
[49] Menstrual cycle dependent variability for serum tumor markers CEA, AFP, CA 19-9, CA 125 and CA 15-3 in healthy women
Erbagci, AB
Yilmaz, N
Kutlar, I
DISEASE MARKERS, 1999, 15 (04) : 259 - 267
[50] Association between tumor markers (CA125, CA15-3) and homozygous sickle cell anemia
Kavvasoglu, Gamze Hande
Kavvasoglu, Baris
Kaya, Hasan
ANNALS OF CLINICAL AND ANALYTICAL MEDICINE, 2022, 13 (12): : 1309 - 1313

← 1 2 3 4 5 →